Literature DB >> 30398528

Use of High-Sensitivity Cardiac Troponin for the Exclusion of Inducible Myocardial Ischemia: A Cohort Study.

Muhammad Hammadah1, Jeong Hwan Kim1, Ayman Samman Tahhan1, Bryan Kindya1, Chang Liu1, Yi-An Ko2, Ibhar Al Mheid1, Kobina Wilmot1, Ronnie Ramadan1, Ayman Alkhoder1, Fahad Choudhary1, Mohamad Mazen Gafeer1, Naser Abdelhadi1, Pratik Pimple2, Pratik Sandesara1, Bruno B Lima1, Amit J Shah3, Laura Ward2, Michael Kutner2, J Douglas Bremner1, David S Sheps4, Paolo Raggi5, Laurence S Sperling1, Viola Vaccarino3, Arshed A Quyyumi1.   

Abstract

Background: Many patients with coronary artery disease (CAD) are routinely referred for surveillance stress testing despite recommendations against it. Objective: To determine whether low levels of resting high-sensitivity cardiac troponin I (hs-cTnI) can identify persons without inducible myocardial ischemia. Design: Observational study. Setting: A university-affiliated hospital network. Patients: Persons with stable CAD: 589 in the derivation group and 118 in the validation cohort. Measurements: Presence of inducible myocardial ischemia was determined by myocardial perfusion imaging with technetium-99m single-photon emission computed tomography during either treadmill or pharmacologic stress testing. Resting plasma hs-cTnI was measured within 1 week of the stress test, and the negative predictive value (NPV) for inducible ischemia was calculated. The derivation cohort was followed for 3 years for incident cardiovascular death and myocardial infarction.
Results: In the derivation cohort, 10 of 101 patients with an hs-cTnI level below 2.5 pg/mL had inducible myocardial ischemia (NPV, 90% [95% CI, 83% to 95%]) and 3 of 101 had inducible ischemia involving at least 10% of the myocardium (NPV, 97% [CI, 92% to 99%]). In the validation cohort, 4 of 32 patients with an hs-cTnI level below 2.5 pg/mL had inducible ischemia (NPV, 88% [CI, 71% to 96%]) and 2 of 32 had ischemia of 10% or greater (NPV, 94% [CI, 79% to 99%]). After a median follow-up of 3 years in the derivation cohort, no adverse events occurred in patients with an hs-cTnI level below 2.5 pg/mL, compared with 33 (7%) cardiovascular deaths or incident myocardial infarctions among those with an hs-cTnI level of 2.5 pg/mL or greater. Limitation: The data may not be applicable to a population without known CAD or to persons with unstable angina, and the modest sample sizes warrant further validation in a larger cohort.
Conclusion: Very low hs-cTnI levels may be useful in excluding inducible myocardial ischemia in patients with stable CAD. Primary Funding Source: National Institutes of Health.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30398528      PMCID: PMC6942174          DOI: 10.7326/M18-0670

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  53 in total

1.  Plasma levels of cardiac troponin I after prolonged strenuous endurance exercise.

Authors:  G Neumayr; H Gaenzer; R Pfister; W Sturm; S P Schwarzacher; G Eibl; G Mitterbauer; H Hoertnagl
Journal:  Am J Cardiol       Date:  2001-02-01       Impact factor: 2.778

2.  Incremental value of a single high-sensitivity cardiac troponin I measurement to rule out myocardial ischemia.

Authors:  Yunus Tanglay; Raphael Twerenbold; Gino Lee; Max Wagener; Ursina Honegger; Christian Puelacher; Tobias Reichlin; Seoung Mann; Seoung Man Sou; Sophie Druey; Thomas Hochgruber; Stephan Zürcher; Milos Radosavac; Philipp Kreutzinger; Gilles Pretre; Fabio Stallone; Petra Hillinger; Cedric Jaeger; Maria Rubini Gimenez; Michael Freese; Damian Wild; Katharina Rentsch; Stefan Osswald; Michael J Zellweger; Christian Mueller
Journal:  Am J Med       Date:  2015-01-30       Impact factor: 4.965

3.  The extent of coronary atherosclerosis is associated with increasing circulating levels of high sensitive cardiac troponin T.

Authors:  Eduard M Laufer; Alma M A Mingels; Mark H M Winkens; Ivo A P G Joosen; Mark W M Schellings; Tim Leiner; Joachim E Wildberger; Jagat Narula; Marja P Van Dieijen-Visser; Leonard Hofstra
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-03-18       Impact factor: 8.311

4.  Pathobiology of troponin elevations: do elevations occur with myocardial ischemia as well as necrosis?

Authors:  Harvey D White
Journal:  J Am Coll Cardiol       Date:  2011-06-14       Impact factor: 24.094

5.  Clinical benefit of high-sensitivity cardiac troponin I in the detection of exercise-induced myocardial ischemia.

Authors:  Gino Lee; Raphael Twerenbold; Yunus Tanglay; Tobias Reichlin; Ursina Honegger; Max Wagener; Cedric Jaeger; Maria Rubini Gimenez; Thomas Hochgruber; Christian Puelacher; Milos Radosavac; Philipp Kreutzinger; Fabio Stallone; Petra Hillinger; Lian Krivoshei; Thomas Herrmann; Romy Mayr; Michael Freese; Damian Wild; Katharina M Rentsch; John Todd; Stefan Osswald; Michael J Zellweger; Christian Mueller
Journal:  Am Heart J       Date:  2015-12-02       Impact factor: 4.749

6.  High-sensitivity cardiac troponin I measurement for risk stratification in a stable high-risk population.

Authors:  Peter A Kavsak; Liqin Xu; Salim Yusuf; Matthew J McQueen
Journal:  Clin Chem       Date:  2011-06-23       Impact factor: 8.327

7.  Association Between High-Sensitivity Cardiac Troponin Levels and Myocardial Ischemia During Mental Stress and Conventional Stress.

Authors:  Muhammad Hammadah; Ibhar Al Mheid; Kobina Wilmot; Ronnie Ramadan; Ayman Alkhoder; Malik Obideen; Naser Abdelhadi; Shuyang Fang; Ijeoma Ibeanu; Pratik Pimple; Heval Mohamed Kelli; Amit J Shah; Brad Pearce; Yan Sun; Ernest V Garcia; Michael Kutner; Qi Long; Laura Ward; J Douglas Bremner; Fabio Esteves; Paolo Raggi; David Sheps; Viola Vaccarino; Arshed A Quyyumi
Journal:  JACC Cardiovasc Imaging       Date:  2017-03-15

8.  Prognostic value of cardiac troponin I measured with a highly sensitive assay in patients with stable coronary artery disease.

Authors:  Torbjørn Omland; Marc A Pfeffer; Scott D Solomon; James A de Lemos; Helge Røsjø; Jūratė Šaltytė Benth; Aldo Maggioni; Michael J Domanski; Jean L Rouleau; Marc S Sabatine; Eugene Braunwald
Journal:  J Am Coll Cardiol       Date:  2013-02-13       Impact factor: 24.094

9.  The Seattle angina questionnaire: reliability and validity in women with chronic stable angina.

Authors:  Laura P Kimble; Sandra B Dunbar; William S Weintraub; Deborah B McGuire; Sharon Fazio; Anindya K De; Ora Strickland
Journal:  Heart Dis       Date:  2002 Jul-Aug

10.  A new equation to estimate glomerular filtration rate.

Authors:  Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh
Journal:  Ann Intern Med       Date:  2009-05-05       Impact factor: 25.391

View more
  4 in total

1.  Relation of High-sensitivity Cardiac Troponin I Elevation With Exercise to Major Adverse Cardiovascular Events in Patients With Coronary Artery Disease.

Authors:  Bruno B Lima; Muhammad Hammadah; Jeong Hwan Kim; Irina Uphoff; Amit Shah; Oleksiy Levantsevych; Zakaria Almuwaqqat; Kasra Moazzami; Samaah Sullivan; Laura Ward; Yan Sun; Michael Kutner; Yi-An Ko; David S Sheps; Agim Beshiri; Gillian Murtagh; J Douglas Bremner; Viola Vaccarino; Arshed A Quyyumi
Journal:  Am J Cardiol       Date:  2020-09-15       Impact factor: 2.778

2.  Cardiopulmonary Exercise Testing and Cardiac Biomarker Measurements in Young Football Players: A Pilot Study.

Authors:  Alexandru-Dan Costache; Mihai Roca; Cezar Honceriu; Irina-Iuliana Costache; Maria-Magdalena Leon-Constantin; Ovidiu Mitu; Radu-Ștefan Miftode; Alexandra Maștaleru; Dan Iliescu-Halițchi; Codruța-Olimpiada Halițchi-Iliescu; Adriana Ion; Ștefania-Teodora Duca; Delia-Melania Popa; Beatrice Abălasei; Veronica Mocanu; Florin Mitu
Journal:  J Clin Med       Date:  2022-05-14       Impact factor: 4.964

3.  The Predictive Approaches to Treatment effect Heterogeneity (PATH) Statement: Explanation and Elaboration.

Authors:  David M Kent; David van Klaveren; Jessica K Paulus; Ralph D'Agostino; Steve Goodman; Rodney Hayward; John P A Ioannidis; Bray Patrick-Lake; Sally Morton; Michael Pencina; Gowri Raman; Joseph S Ross; Harry P Selker; Ravi Varadhan; Andrew Vickers; John B Wong; Ewout W Steyerberg
Journal:  Ann Intern Med       Date:  2019-11-12       Impact factor: 25.391

4.  Soluble Urokinase-Type Plasminogen Activator Receptor and High-Sensitivity Troponin Levels Predict Outcomes in Nonobstructive Coronary Artery Disease.

Authors:  Ahmed Al-Badri; Ayman Samman Tahhan; Nabil Sabbak; Ayman Alkhoder; Chang Liu; Yi-An Ko; Viola Vaccarino; Afif Martini; Arianna Sidoti; Cydney Goodwin; Bahjat Ghazzal; Agim Beshiri; Gillian Murtagh; Puja K Mehta; Arshed A Quyyumi
Journal:  J Am Heart Assoc       Date:  2020-04-17       Impact factor: 5.501

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.